Finoriq research workspace
BIO-RAD LABORATORIES, INC. (BIO) Historical Metrics
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical. Review BIO fundamentals, ratios, and historical filing metrics on Finoriq.
Company Snapshot
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
- Company
- BIO-RAD LABORATORIES, INC. (BIO)
- Ticker
- BIO
- Market Cap
- $8.1B
- Latest Price
- $303.56
- Industry
- Life Science Tools
BIO-RAD LABORATORIES, INC. (BIO) Current Valuation Metrics
Static valuation preview for BIO-RAD LABORATORIES, INC. (BIO). Market data retrieved 2026-07-08. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| P/EMarket cap divided by latest TTM net income. | 44.8x | Net Income | TTM Q1 2026 |
| P/SMarket cap divided by latest TTM revenue. | 2.92x | Revenue | TTM Q1 2026 |
| P/Operating Cash FlowMarket cap divided by latest TTM operating cash flow. | 14.8x | Operating Cash Flow | TTM Q1 2026 |
| Earnings YieldLatest TTM net income divided by market cap. | 2.2% | Net Income | TTM Q1 2026 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | 6.7% | Operating Cash Flow | TTM Q1 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.